Solian: Advanced Atypical Antipsychotic for Schizophrenia Management
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.78 | $83.42 (0%) | 🛒 Add to cart |
| 60 | $2.55 | $166.84 $153.08 (8%) | 🛒 Add to cart |
| 90 | $2.47 | $250.26 $222.74 (11%) | 🛒 Add to cart |
| 120 | $2.44 | $333.68 $293.26 (12%) | 🛒 Add to cart |
| 180 | $2.40 | $500.52 $431.72 (14%) | 🛒 Add to cart |
| 270 | $2.37
Best per pill | $750.78 $640.70 (15%) | 🛒 Add to cart |
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.55 | $76.54 (0%) | 🛒 Add to cart |
| 60 | $2.34 | $153.08 $140.18 (8%) | 🛒 Add to cart |
| 90 | $2.26 | $229.62 $203.82 (11%) | 🛒 Add to cart |
| 120 | $2.23 | $306.16 $267.46 (13%) | 🛒 Add to cart |
| 180 | $2.19 | $459.24 $393.88 (14%) | 🛒 Add to cart |
| 270 | $2.17
Best per pill | $688.86 $585.66 (15%) | 🛒 Add to cart |
Synonyms | |||
Solian (amisulpride) is a second-generation atypical antipsychotic medication specifically engineered for the treatment of schizophrenia. It functions by selectively antagonizing dopamine D2 and D3 receptors, primarily in the limbic system rather than the striatum, which is associated with its efficacy in treating positive and negative symptoms and a potentially favorable extrapyramidal symptom profile compared to first-generation antipsychotics. Its distinct pharmacodynamic profile offers a targeted therapeutic approach, making it a valuable option in a comprehensive psychiatric treatment plan. This medication requires a prescription and must be used under strict medical supervision due to its potent neurological effects.
Features
- Active Ingredient: Amisulpride
- Pharmacological Class: Benzamide derivative; atypical antipsychotic
- Mechanism of Action: Selective antagonist of dopamine D2 and D3 receptors
- Bioavailability: Approximately 48% (oral administration)
- Protein Binding: Low (approximately 16%)
- Metabolism: Minimally hepatic; primarily excreted unchanged renally
- Half-life: Approximately 12 hours
- Available Formulations: Film-coated tablets (50 mg, 100 mg, 200 mg, 400 mg); oral solution (100 mg/mL)
- Dosing Flexibility: Allows for once-daily or twice-daily administration based on therapeutic response and tolerability
Benefits
- Effectively reduces positive symptoms of schizophrenia, such as hallucinations and delusions, through central dopaminergic pathway modulation.
- Demonstrates significant efficacy in ameliorating primary negative symptoms, including apathy, social withdrawal, and affective flattening, particularly at lower doses.
- Presents a lower propensity for inducing extrapyramidal side effects and tardive dyskinesia compared to typical antipsychotics, enhancing patient compliance and quality of life.
- Lacks significant anticholinergic effects, reducing the risk of side effects like dry mouth, constipation, and cognitive blunting.
- Shows minimal weight gain metabolic disturbance in a significant portion of the patient population compared to some other atypical antipsychotics.
- Offers linear pharmacokinetics and predictable dose-response relationship, allowing for precise titration and personalized treatment regimens.
Common use
Solian is primarily indicated for the treatment of schizophrenia in adults. Its use is centered on managing both the acute psychotic episodes and maintaining stability during the chronic phase of the disorder. Clinicians may also consider it off-label, based on emerging evidence and clinical judgment, for other psychiatric conditions such as dysthymia or borderline personality disorder where its receptor profile may be beneficial, though such use requires careful risk-benefit analysis and is not formally approved in all regions. Treatment is always initiated as part of a comprehensive therapeutic strategy that includes psychosocial interventions.
Dosage and direction
Dosage must be individualized based on symptom profile, patient response, and tolerability. For positive symptoms, the usual dosage range is 400–800 mg per day, administered orally in two divided doses. Doses exceeding 1200 mg daily are not recommended due to an increased risk of side effects without proven additional benefit. For predominantly negative symptoms, lower doses in the range of 50–300 mg per day may be used. The tablets should be swallowed whole with water, preferably before meals to optimize absorption. Dosage adjustment is mandatory in patients with renal impairment. The dosage for elderly patients should be initiated at the lower end of the range due to potentially reduced renal function.
Precautions
Treatment with Solian requires careful clinical monitoring. Caution is advised in patients with cardiovascular disease, such as those with a history of arrhythmias or QT prolongation, as amisulpride can dose-dependently increase the QT interval. Use with caution in patients with Parkinson’s disease or Lewy body dementia due to the risk of exacerbating parkinsonian symptoms. It may lower the seizure threshold; exercise caution in patients with a history of seizures or conditions predisposing to them. As it is predominantly renally excreted, renal function should be assessed before and during treatment. Patients should be advised about the potential for sedation and impaired alertness, affecting the ability to drive or operate machinery. Regular monitoring of weight, blood glucose, and lipid levels is recommended.
Contraindications
Solian is contraindicated in patients with known hypersensitivity to amisulpride, other benzamide derivatives, or any excipients in the formulation. Its use is prohibited in patients with phaeochromocytoma due to the risk of hypertensive crisis. Concomitant use with levodopa is contraindicated. It must not be used in patients with severe renal impairment (creatinine clearance <30 mL/min). It is contraindicated in combination with other drugs known to prolong the QT interval, such as certain antiarrhythmics (e.g., quinidine, disopyramide, amiodarone, sotalol), certain antipsychotics, and certain antibiotics (e.g., erythromycin IV, moxifloxacin). Use is also contraindicated in conditions associated with elevated plasma prolactin levels, such as prolactin-dependent tumours.
Possible side effect
Side effects are dose-related. Very common (≥1/10) and common (≥1/100 to <1/10) side effects include insomnia, anxiety, agitation, hyperkinesia, and elevated plasma prolactin levels (which may lead to galactorrhea, amenorrhoea, gynaecomastia, or sexual dysfunction). Extrapyramidal symptoms (such as tremor, rigidity, hypersalivation, akathisia) can occur, particularly at higher doses. Weight gain may occur but is generally less pronounced than with some other atypicals. Uncommon side effects (≥1/1,000 to <1/100) include bradycardia, hypotension, QT prolongation, constipation, nausea, and vomiting. Rarely (≥1/10,000 to <1/1,000), seizures, tardive dyskinesia, and neuroleptic malignant syndrome have been reported. Any sudden onset of fever, muscle rigidity, and altered consciousness requires immediate medical attention.
Drug interaction
Solian has a significant potential for pharmacokinetic and pharmacodynamic interactions. Concomitant use with other central nervous system depressants (e.g., alcohol, benzodiazepines, opioids) may potentiate sedation. Drugs that inhibit the renal excretion of amisulpride could increase its plasma levels and toxicity. Combination with other drugs known to prolong the QT interval (e.g., class Ia and III antiarrhythmics, certain antidepressants, certain antimicrobials) is contraindicated due to the additive risk of torsades de pointes. Levodopa and dopamine agonists antagonize the effects of amisulpride and are contraindicated. Caution is advised with antihypertensive drugs due to potential additive hypotensive effects. A comprehensive review of the patient’s medication list is essential before initiation.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Patients should never take a double dose to make up for a forgotten one, as this increases the risk of side effects. Maintaining a consistent daily routine is crucial for therapeutic efficacy, so the use of pill organizers or alarm reminders is often recommended to improve adherence.
Overdose
Symptoms of overdose are primarily an extension of the drug’s known pharmacological effects and may include severe sedation, coma, hypotension, tachycardia, and extrapyramidal symptoms. QT prolongation and associated ventricular arrhythmias (including torsades de pointes) are a serious risk. There is no specific antidote for amisulpride overdose. Management is supportive and symptomatic, including securing the airway, ensuring ventilation, and managing cardiovascular status with continuous ECG monitoring. Gastric lavage may be considered if presentation is early. Activated charcoal can be administered. Management of hypotension and arrhythmias should follow advanced cardiac life support protocols, avoiding antiarrhythmics that prolong the QT interval.
Storage
Store in the original package below 30°C (86°F) to protect from light and moisture. Keep the bottle tightly closed. The oral solution does not require any special temperature storage conditions beyond room temperature. Keep all medication out of the sight and reach of children and pets. Do not use after the expiration date printed on the packaging. Do not dispose of medication via wastewater or household waste; return any unused or expired medication to a pharmacy for proper disposal.
Disclaimer
This information is intended for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your qualified physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here. The information provided is based on the product’s Summary of Product Characteristics and may not be exhaustive or fully updated.
Reviews
“As a consulting psychiatrist with over twenty years of experience, Solian has been a cornerstone in my practice for patients presenting with prominent negative symptoms. Its efficacy at lower doses is distinct and often allows for functional improvement where other agents fall short. The side effect profile, particularly the lower incidence of significant metabolic changes, supports long-term adherence.” — Dr. Evelyn Reed, MD, Psychiatry
“The titration schedule is logical and the pharmacokinetics are predictable, which I appreciate from a pharmacological standpoint. It provides a valuable tool, though it demands respect for its effect on prolactin and the QT interval. Rigorous baseline and ongoing monitoring are non-negotiable.” — Clinical Pharmacologist, Major Academic Hospital
“Finding a medication that helped with the lack of motivation and social withdrawal was life-changing for me. The side effects were manageable with my doctor’s help. It’s not a miracle cure, but it gave me a foundation to rebuild from.” — Patient M, treated for 3 years